Stockreport

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success [Seeking Alpha]

Roivant Sciences Ltd.  (ROIV) 
PDF The company has a differentiated drug development pipeline targeting multi-billion dollar indications, thanks to its unique "Vant" subsidiaries and some smart dealmakin [Read more]